EUMYCETOMA BY Madurella grisea: REPORT OF THE FIRST CASE OBSERVED IN THE SOUTHERN BRAZILIAN REGION

Severo, Luiz Carlos; Vetoratto, G.; Oliveira, F. De Mattos; Londero, Alberto Thomaz

doi:10.1590/s0036-46651999000200013

Cited by 5 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thiabendazole, a commonly used antihelmintic, is effective in less than 50% 41 of patients, but its use is limited by gastrointestinal toxicities, especially at doses greater than 2 g daily 5,41 . A few case reports describe the clinical efficacy of terbinafine used alone 17,47 or in combination with heat therapy 50 . ESTERRE et al reported mycologic cure of chromoblastomycosis in 85.2% (23/27) of patients after 12 months of terbinafine therapy 18 .…”

Section: Discussionmentioning

confidence: 99%

Posaconazole treatment of refractory eumycetoma and chromoblastomycosis

Negroni¹,

Tobón

Bustamante

et al. 2005

Rev. Inst. Med. trop. S. Paulo

128

View full text Add to dashboard

Eumycetoma and chromoblastomycosis are chronic, disfiguring fungal infections of the subcutaneous tissue that rarely resolve spontaneously. Most patients do not achieve sustained long-term benefits from available treatments; therefore, new therapeutic options are needed. We evaluated the efficacy of posaconazole, a new extended-spectrum triazole antifungal agent, in 12 patients with eumycetoma or chromoblastomycosis refractory to existing antifungal therapies. Posaconazole 800 mg/d was given in divided doses for a maximum of 34 months. Complete or partial clinical response was considered a success; stable disease or failure was considered a nonsuccess. All 12 patients had proven infections refractory to standard therapy. Clinical success was reported for five of six patients with eumycetoma and five of six patients with chromoblastomycosis. Two patients were reported to have stable disease. As part of a treatment-use extension protocol, two patients with eumycetoma who initially had successful outcome were successfully retreated with posaconazole after a treatment hiatus of > 10 months. Posaconazole was well tolerated during long-term administration (up to 1015 d). Posaconazole therapy resulted in successful outcome in most patients with eumycetoma or chromoblastomycosis refractory to standard therapies, suggesting that posaconazole may be an important treatment option for these diseases.

show abstract

Section: Discussionmentioning

confidence: 99%

Posaconazole treatment of refractory eumycetoma and chromoblastomycosis

Negroni¹,

Tobón

Bustamante

et al. 2005

Rev. Inst. Med. trop. S. Paulo

128

View full text Add to dashboard

show abstract

“…Madurella grisea) is phylogenetically-affiliated to the Trematosphaeriaceae family, suborder Massarineae in the Pleosporales order [6]. Although not so common, T. grisea has long been acknowledged as an exclusive agent of mycetoma in South America, more precisely in Brazil [10,11] and in Chile (but also in a submandibular abscess in India [6]. However, demonstration of its involvement in phaeohyphomycosis is more recent, maybe because there was previously a lack of correct identification [12].…”

mentioning

confidence: 99%

Successful Terbinafine Treatment for Cutaneous Phaeohyphomycosis Caused by Trematosphaeria grisea in a Heart Transplanted Man: Case Report and Literature Review

Mercier¹,

Bastides²,

Bailly

et al. 2020

Mycopathologia

View full text Add to dashboard

Phaeohyphomycosis is chronic infectious disease caused by dematiaceous fungi. It is characterized by the presence of pigmented septate mycelia within tissues. In case of superficial infection, the lesion(s) chronically evolve towards painless pseudo-tumors of the soft parts. We report herein the original case of a heart transplanted man who exhibited phaeohyphomycosis of the left hand, with no mention of travels in endemic areas. Trematosphaeria grisea was identified as the causative agent, which is quite innovative since this species has been rather described in mycetoma. The antifungal treatment initially based on isavuconazole alone was not sufficient to cure the patient. In contrast, its association with local terbinafine ointment allowed totalclinical improvement. This finding is unusual as diagnosis of phaeohyphomycosis caused by T. grisea is uncommon in non-tropical countries, and as the outcome appeared successful by the means of add-on therapeutic strategy with terbinafine.

show abstract

EUMYCETOMA BY Madurella grisea: REPORT OF THE FIRST CASE OBSERVED IN THE SOUTHERN BRAZILIAN REGION

Abstract: The first case of eumycetoma by Madurella grisea occurred in Southern Brazilian Region is herein related. In addition, Brazilian literature on this subject was reviewed and, the geographic distribution of this eumycetoma is presented.

Cited by 5 publications

References 8 publications

Posaconazole treatment of refractory eumycetoma and chromoblastomycosis

Posaconazole treatment of refractory eumycetoma and chromoblastomycosis

Successful Terbinafine Treatment for Cutaneous Phaeohyphomycosis Caused by Trematosphaeria grisea in a Heart Transplanted Man: Case Report and Literature Review

Contact Info

Product

Resources

About